This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	HER2 (EGFR2; ERBB2; neu); VEGF	<p>Studies in mice and in cell culture suggest that a combination of HER2 and VEGF peptide mimics could help treat cancer. In human cancer cell lines, the combination led to greater inhibition of cell growth than either peptide alone. In a mouse model of breast cancer, the combination resulted in better tumor growth inhibition than either peptide alone ($p < 0.001$). Next steps include moving the VEGF and HER2 peptide mimic combination into clinical trials.</p> <p>SciBX 4(10); doi:10.1038/scibx.2011.277 Published online March 10, 2011</p>	Peptide mimics covered by multiple patents; available for licensing	<p>Vicari, D. <i>et al. J. Biol. Chem.</i>; published online Feb. 14, 2011; doi:10.1074/jbc.M110.216812</p> <p>Foy, K.C. <i>et al. J. Biol. Chem.</i>; published online Feb. 16, 2011; doi:10.1074/jbc.M110.216820</p> <p>Contact: Pravin T.P. Kaumaya, The Ohio State University Medical Center, Columbus, Ohio e-mail: kaumaya.1@osu.edu</p>